Phylloceuticals

Phylloceuticals is a technology company that utilizes a proprietary plant-based platform to produce therapeutic proteins and biosimilars. By leveraging plant cell systems, the company aims to streamline the development and manufacturing of biologics, offering a production method that is designed to be safer, faster, and more cost-effective than traditional processes. Their platform is engineered to handle complex requirements such as protein folding and sugar optimization, providing a scalable solution that can rapidly screen high numbers of candidates, including bispecific antibodies and PD-1 inhibitors. The company maintains a modular, non-binary approach that allows it to pivot quickly to meet changing market demands.

This technology provides significant value to commercialization partners, healthcare systems, and the animal health industry by accelerating the transition from research to production. By producing biosimilars at a fraction of the cost, Phylloceuticals enables partners to expedite screening timelines and bring therapeutics to market more efficiently. The company has demonstrated its production capabilities, including the development of PD-1 inhibitors, and operates with a mission to improve global access to advanced medicines while ensuring high standards of safety and sourcing transparency. Through its speed-to-screen capabilities, the company also bridges the gap between AI-driven candidate discovery and physical manufacturing.